global target, page-9

Clearly, the interest in HGR is predicated on the anticipated FUTURE financial performance, not the PAST (which is what you are basing your forecasts on). The market has responded because they recognise the potential of Oraline (and other products) in the context of rapidly-occuring change, vis:

1. migration from urine to oral testing
2. imminent FDA clearance (required for many potential buyers)
3. growth in political support of illicit drug testing
4. new markets - eg Mexican schools testing, roadside testing (as well as already established markets eg workplace testing)

You know as well as I do, that HGR do not need an army of sales and marketing people - because they have existing relationships with an army of well-established distributors (eg the Mexican schools opportunity)